Area of research
Genetics · Pulmonary and Respiratory Medicine · imunotherapy
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer Genomics and Diagnostics, Radiomics and Machine Learning in Medical Imaging, and Brain Metastases and Treatment.
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder
Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Functional analysis of <i>MSH2</i> unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair
Interlaboratory comparison of IDH mutation detection